Skip to main content

What the FDA labels say about taking them together

Mifepristone and rifampin

Mifepristone's FDA label of September 25, 2025 names rifampin in its drug interactions section; the rifampin label PlainMeds reads does not name mifepristone. The mifepristone label: “Avoid co-administration of mifepristone and CYP3A inducers such as rifampin, rifabutin, rifapentin, phenobarbital, phenytoin, carbamazepine, and St. John's wort.”

Check it at the source: the mifepristone FDA label on DailyMed (effective September 25, 2025, Corcept Therapeutics Incorporated); the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.).

What does the mifepristone label say about rifampin?

Mifepristone label, drug interactions

Avoid co-administration of mifepristone and CYP3A inducers such as rifampin, rifabutin, rifapentin, phenobarbital, phenytoin, carbamazepine, and St. John's wort.

Source: FDA drug label (Mifepristone), Corcept Therapeutics Incorporated, effective September 25, 2025 (SPL set 63c068cd-9370-460f-829b-70e8c7ebe91e), via openFDA; the full label on DailyMed

What does the rifampin label say about mifepristone?

Rifampin's label (effective February 11, 2026) does not name mifepristone in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

3Mifepristone generic labelers
13Rifampin generic labelers
MifepristoneRifampin
Labeled forn/an/a
Boxed warningYesNo
Pharmacy cost (NADAC)n/a$0.679 per capsule 300 mg capsule
Shortage nowNo current entryIn shortage

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?